Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence and Dose Proportionality of Griseofulvin in Healthy Adults
NCT04318535Phase 1Completed
- Sponsor
- GSK
- Start
- Jan 2020
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of griseofulvin in dermatophytosis (3 arms), sponsored by GSK. Primary endpoints: Maximum Plasma Concentration, Area Under Plasma Concentration-time Curve From Zero Hours to Time of Last Quantifiable Concentration and 3 more. Started Jan 2020; status: completed.
02
Drugs
griseofulvin
03
Conditions
dermatophytosis
Beyond the preview
Go deeper on NCT04318535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04318535.